ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
ABSCIENCES

BRIEF

published on 10/17/2024 at 19:33, 1 month 3 days ago

AB Science fait face à un échec dans l'approbation par l'EMA du traitement de la SLA

Autorisation De Mise Sur Le Marché Masitinib Sciences AB Traitement De La SLA Décision De L'EMA
BRIEF

published on 10/17/2024 at 19:33, 1 month 3 days ago

AB Science Faces Setback in EMA Approval for ALS Treatment

AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
PRESS RELEASE

published on 10/17/2024 at 19:28, 1 month 3 days ago

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
AB Science annonce un avis négatif de l'EMA sur la demande d'autorisation de mise sur le marché du masitinib pour la SLA malgré des résultats encourageants. La société se concentre sur l'étude confirmatoire

AB Science Masitinib Étude Confirmatoire EMA SLA
PRESS RELEASE

published on 10/17/2024 at 19:28, 1 month 3 days ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science provides an update on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis. EMA confirms negative opinion but company remains focused on confirmatory phase 3 program

Phase 3 Program AB Science Masitinib Amyotrophic Lateral Sclerosis Conditional Marketing Authorisation
PRESS RELEASE

published on 10/11/2024 at 18:08, 1 month 9 days ago

Rapport financier semestriel 2024
PRESS RELEASE

published on 10/11/2024 at 18:01, 1 month 9 days ago

Rapport financier semestriel 2024
PRESS RELEASE

published on 10/10/2024 at 11:55, 1 month 10 days ago

Rapport financier semestriel 2024
BRIEF

published on 10/10/2024 at 08:32, 1 month 11 days ago

AB Science Reports Mid-2024 Financial Results and Clinical Developments

Financial Results Clinical Trials Capital Increase AB Science Masitinib
BRIEF

published on 10/10/2024 at 08:32, 1 month 11 days ago

AB Science publie ses résultats financiers et ses développements cliniques pour la mi-2024

Résultats Financiers Augmentation De Capital Essais Cliniques Masitinib Sciences AB
PRESS RELEASE

published on 10/10/2024 at 08:27, 1 month 11 days ago

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science
AB Science présente ses résultats financiers au premier semestre 2024 et les événements clés de la période, incluant le développement du masitinib, les résultats positifs dans la Covid-19 et le renforcement de la propriété intellectuelle

Résultats Financiers COVID-19 Développement Clinique AB Science Masitinib

1 2 ... 4

Accesswire

Published on 11/21/2024 at 09:00, 45 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 10 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 20 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 45 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 45 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 44 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 46 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 46 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 30 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 36 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 47 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 47 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 47 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 38 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 25 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE